Real-world outcomes of faricimab in treating diabetic macular edema up to two years
Indian Journal of Ophthalmology · 2025
DOI: 10.4103/ijo.ijo_930_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Ophthalmology, 2025. Verfasst von Tanvi Khetan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Department, Barts Health NHS Trust, London, United Kingdom. Hauptthemen laut MEDLINE: Macular Edema, Visual Acuity, Diabetic Retinopathy, Macula Lutea. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
To evaluate real-world outcomes of faricimab in treating diabetic macular edema (DMO) in treatment-naive and treatment-switch patients.
Design
Retrospective audit.
Methods
All patients with DMO initiating 6 mg faricimab at a London hospital between 01/01/2022-02/02/2024 were included. The protocol comprised four four-weekly loading doses followed by a treat-and-extend regimen tailored to response. Data collected included demographics, best-corrected visual acuity (BCVA), and central macular thickness (CMT).
Results
Overall, 65 patients (87 eyes) received faricimab; 34 eyes (39.1%) were treatment-naive, and 53 eyes (60.9%) had switched from other treatments. In the treatment-naive group (24 patients; mean follow-up 8 months, SD = 3.8; 3–8 injections), mean age was 66 years (SD = 10), baseline VA: 59.5 EDTRS (SD = 13), and CMT: 485.1 μm (SD = 80), reducing to 327.2 μm (SD = 70; P < 0.0001). Final VA was 62.7 EDTRS (SD = 14; P = 0.259). The treatment-switched group (41 patients, 53 eyes) had a mean age of 65 (SD = 11) years. A total of 32 eyes (60.4%) had a single prior treatment; 25 had received aflibercept, four eyes had received ranibizumab, and three eyes had received dexamethasone implants. The other 21 (39.6%) eyes had combinations of these medications. Patients received 2–11 faricimab injections. Mean follow-up was 8.4 months (SD = 3.9), initial VA: 59.7 EDTRS (SD = 12.9), and CMT: 439.5 μm (SD = 102), decreasing to 366.9 μm (SD = 80.7) ( P < 0.0001); final VA was 61.4 (SD = 15.4) ( P = 0.55).
Conclusion
Faricimab significantly reduced CMT in both groups, with a greater reduction in treatment-naive eyes. VA improvement was, however, not statistically significant. Further studies are warranted to explore factors influencing visual outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ophthalmology Department, Barts Health NHS Trust, London, United Kingdom.
Zitieren
APA
Khetan, T., Shah, P., Ahmed, S., Jeyabaladevan, P., & Vithlani, S. (2025). Real-world outcomes of faricimab in treating diabetic macular edema up to two years. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_930_25
Vancouver
Khetan T, Shah P, Ahmed S, Jeyabaladevan P, Vithlani S. Real-world outcomes of faricimab in treating diabetic macular edema up to two years. Indian Journal of Ophthalmology. 2025. doi:10.4103/ijo.ijo_930_25
BibTeX
@article{Khetan2025,
author = {Khetan, Tanvi and Shah, Prachi and Ahmed, Syed and Jeyabaladevan, Priyancaa and Vithlani, Sejal},
title = {Real-world outcomes of faricimab in treating diabetic macular edema up to two years},
journal = {Indian Journal of Ophthalmology},
year = {2025},
doi = {10.4103/ijo.ijo_930_25}
}
EUVIMED